Please login to the form below

Not currently logged in
Email:
Password:

GSK Biologicals signs Alzheimer's deal with AFFiRiS

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates.

The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. This allows the development of proteins that bind to the disease-causing human proteins that are central to the pathology of Alzheimer's disease.

Jean Stephenne, president and general manager of GlaxoSmithKline Biologicals said: "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty payments. In the event of the vaccines reaching full commercial success and gaining government authority approval, the value of the agreement could reach £334m.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics